Analytical methodologies for the quantitation of platinum anti-cancer drugs and related compounds in biological media

Waal, W.A.J. De; Maessen, F.J.M.J.; Kraak, J.C.

doi:10.1016/0731-7085(90)80003-8

Cited by 43 publications

(12 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mean noncompartmental pharmacokinetic parameters for gemcitabine and cisplatin during days 1, 8, and 22 are depicted in Table 2. These parameters were consistent with those reported previously in the literature (28,29,32). In general, plasma concentrations of gemcitabine were similar on day 1 (before the start of LY900003 infusion) and day 8 (during the LY900003 infusion) and declined in an apparent multiexponential fashion over time.…”

Section: Partsupporting

confidence: 80%

“…Gemcitabine concentrations were assayed by a high-performance liquid chromatography method with a lower limit of quantitation (LLOQ) of 0.15 g/mL (28), cisplatin concentrations were assayed through atomic absorption spectrophotometry (LLOQ, 0.05 g/mL; ref. 29), and concentrations of LY900003 and its chain-shortened metabolite by capillary gel electrophoresis (LLOQ, 0.206 g/mL) were assayed as described previously (22).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-α, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non–Small Cell Lung Cancer

Villalona‐Calero

Ritch

Figueroa³

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Protein kinase C-␣ has been implicated in malignant transformation and proliferation. Based on in vivo superadditive interaction between the protein kinase C-␣ antisense oligonucleotide LY900003 (Affinitak, ISIS 3521) and cisplatin, we designed this phase I/II trial of LY900003 with cisplatin/gemcitabine Experimental Design: The safety of the combination, as well as potential pharmacokinetic interactions, was evaluated in the phase I portion of the trial. The phase II portion evaluated the antitumor activity of the combination in previously untreated patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).Results: Seven patients received 18 cycles of the combination during the phase I portion. Dose-limiting toxicity was only observed in one of six evaluable patients (grade 3 fatigue). However, due to a relatively high frequency of thrombocytopenia, cisplatin 80 (mg/m 2 ) and gemcitabine (1,000 mg/m 2 ) were recommended for the phase II portion.Antitumor activity was observed in two patients (one with NSCLC and one with pancreatic carcinoma), and prolonged stabilization was observed in two others. No pharmacokinetic interactions occurred. In the phase II portion, 55 NSCLC patients received the combination at two gemcitabine doses [1,000 mg/m 2 , n ‫؍‬ 44 (original cohort); 1,250 mg/m 2 , n ‫؍‬ 11 (expanded cohort)]. Fourteen of 39 evaluable patients in the original cohort had a response rate (1 complete response and 13 partial responses; response, 36%), whereas 2 of 9 evaluable patients in the expanded cohort experienced partial response (combined response rate, 33%). The median time to treatment failure was 3.9 months, whereas the median time response to progression for the 48 patients with evaluable response was 4.4 months (confidence interval, 3.5-5.5 months). Intent to treat median survival time was 8.9 months. Forty-eight percent of the patients experienced catheter-related events.Conclusions: LY900003 can be administered safely in combination with cisplatin and gemcitabine and is associated with antitumor activity in patients with advanced NSCLC. Better characterization of subsets of patients most likely to benefit from this combination therapy is needed.

show abstract

Section: Partsupporting

confidence: 80%

Section: Methodsmentioning

confidence: 99%

A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-α, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non–Small Cell Lung Cancer

Villalona‐Calero

Ritch

Figueroa³

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…A common approach for determining the concentration of cisplatin has been to measure the total platinum content of blood fractions and other biological fluids by flame and graphite furnace atomic absorption spectrometry (GFAAS), inductively coupled plasma atomic emission spectrometry (ICP-AES) and inductively coupled plasma mass spectrometry (ICP-MS) [5]. To avoid detection of platinum that may have become deactivated by reactions with plasma proteins, plasma is often deproteinized by solvent protein precipitation or ultrafiltration before analysis.…”

Section: Introductionmentioning

confidence: 99%

Specific determination of intact cisplatin and monohydrated cisplatin in human plasma and culture medium ultrafiltrates using HPLC on-line with inductively coupled plasma mass spectrometry

Bell

Liu

Tingle

et al. 2006

Journal of Chromatography B

View full text Add to dashboard Cite

“…This technique has been used with ICP-OES detection [40][41] and ICP-MS detection [42]. Alternatively anion exchange columns can be used, and have been used successfully with ICP-MS detection [43].…”

Section: Introductionmentioning

confidence: 98%

A high performance liquid chromatography ? inductively coupled plasma-mass spectrometry interface employing desolvation for speciation studies of platinum in chemotherapy drugs

Cairns

Ebdon

Hill

1996

Analytical and Bioanalytical Chemistry

View full text Add to dashboard Cite

A novel interface between high performance liquid chromatography (HPLC) and inductively coupled plasma-mass spectrometry (ICP-MS) is described. The eluent from the HPLC is nebulised into a heated cyclone spray-chamber and the solvent removed using a Nafion membrane drier, held at 75 degrees C, and a cryogenic condenser. The condenser consists of 6 Peltier heat pumps connected to liquid cooled aluminium blocks. At a nebuliser gas flow rate of 0.6 l min(-1), the membrane drier removes 58% of the vapour and the Peltier condenser 75% of the remaining vapour, i.e. a total desolvation efficiency of 89%. This enables the use of HPLC solvents which otherwise would destabilise the ICP, e.g. 100% acetonitrile or methanol, and permits the use of solvent gradients with minimal baseline drift. The system has been applied to the determination of platinum species in an organoplatinum drug used for chemotherapy in human plasma ultrafiltrate of patients treated with this new drug (JM-216). The limit of detection for platinum species has been 0.6 ng nl(-1) (i.e. 120 pg of Pt) and several species have been separated with good resolution.

show abstract

Analytical methodologies for the quantitation of platinum anti-cancer drugs and related compounds in biological media

Cited by 43 publications

References 96 publications

A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-α, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non–Small Cell Lung Cancer

A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-α, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non–Small Cell Lung Cancer

Specific determination of intact cisplatin and monohydrated cisplatin in human plasma and culture medium ultrafiltrates using HPLC on-line with inductively coupled plasma mass spectrometry

A high performance liquid chromatography ? inductively coupled plasma-mass spectrometry interface employing desolvation for speciation studies of platinum in chemotherapy drugs

Contact Info

Product

Resources

About